Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Anh DD, Baiqing D, Bhutta Z, Sur D, Whittington D. Cost of illness due to typhoid fever in five Asian countries. Trop Med Int Health. 2011 Mar 1;16(3):314-23.
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.